Form 4: Agenus CEO Garo Armen Receives Stock in Lieu of Salary

Agenus Inc. CEO Garo H. Armen received 4,233 shares of common stock as compensation for his salary for the period ending May 1, 2026.

Summary

• CEO Garo H. Armen was issued 4,233 shares of Agenus Inc. common stock.
• The issuance was made in lieu of a cash salary payment for the pay period ending May 1, 2026.
• The shares were valued at $3.84 per share, based on the closing price on the payroll date.
• The shares are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices rather than a change in company outlook.

Positives

• The transaction demonstrates the CEO's alignment with shareholders by accepting equity compensation instead of cash.
• The issuance preserves company cash reserves.

Negatives

• The issuance results in minor dilution to existing shareholders.

Risks

• Continued reliance on equity-based compensation may signal cash flow constraints within the company.

Future Outlook

The filing does not provide forward-looking guidance regarding company performance, but indicates the continuation of the CEO's compensation arrangement involving equity in lieu of cash.

Management Comments

• The issuance of shares was requested by the reporting person and approved by the Agenus Inc. Compensation Committee.

Industry Context

StockSavvy.ai notes that it is common for early-stage or cash-constrained biotechnology companies to utilize equity-based compensation for executives to preserve capital for R&D and clinical trials.

Comparison to Industry Standards

• The practice of paying executive salaries in stock is a standard mechanism in the biotech sector to manage liquidity.
• The use of the 2019 Equity Incentive Plan aligns with standard corporate governance practices for equity compensation.

Related Party Transactions

• The reporting person holds shares in IRA accounts and acts as a trustee for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new shares.

Next Steps

• Continued monitoring of executive compensation filings for future salary-to-equity conversions.

Key Dates

Keywords

Agenus, AGEN, Insider Trading, Form 4, Executive Compensation, Equity Incentive Plan